CD47 is the best studied in antitumor treatment, and anti-CD47 antibody-based therapies targeting the CD47-SIRPα axis enhance the phagocytosis of cancer cells by macrophages (Zhang W. et al., 2020). This evidence concerns the gene CD47 and cancer.